Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
J Clin Invest. 2024 Oct 15;134(20):e172887. doi: 10.1172/JCI172887.
Cannabis has been legalized for medical and recreational purposes in multiple countries. A large number of people are using cannabis and some will develop cannabis use disorder (CUD). There is a growing recognition that CUD requires specific interventions. This Review will cover this topic from a variety of perspectives, with a particular emphasis on neurobiological findings and innovative treatment approaches that are being pursued. We will first describe the epidemiology and burden of disease of CUD, including risk factors associated with CUD (both in terms of general risk and genetic risk variants). Neurobiological alterations identified in brain imaging studies will be presented. Several psychosocial interventions that are useful for the management of CUD, including motivational enhancement therapy, behavioral and cognitive therapy, and contingency management, will be covered. Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.
大麻已在多个国家被合法化用于医疗和娱乐目的。大量的人正在使用大麻，其中一些人将患上大麻使用障碍（CUD）。人们越来越认识到，CUD 需要特定的干预措施。这篇综述将从多个角度涵盖这个话题，特别强调神经生物学发现和正在探索的创新治疗方法。我们将首先描述 CUD 的流行病学和疾病负担，包括与 CUD 相关的风险因素（既有一般风险因素，也有遗传风险变异）。将介绍在脑成像研究中发现的神经生物学改变。涵盖了几种对 CUD 管理有用的心理社会干预措施，包括动机增强疗法、行为和认知疗法以及后果管理。虽然目前还没有批准用于 CUD 的药物干预措施，但我们介绍了正在测试的最有前途的药物干预措施。
